CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients

  1. R Venegas-Rodriguez
  2. R Santana-Sanchez
  3. R Peña-Ruiz
  4. M Bequet-Romero
  5. M Hernandez-Cedeño
  6. B Santiesteban-Licea
  7. A Garcia
  8. PR Aroche
  9. D Oliva-Perez
  10. LM Ortega-Gonzalez
  11. J E Baldomero
  12. LR Cruz
  13. G Guillén
  14. G Martinez-Donato
  15. MC Dominguez-Horta
  16. for the CIGB-258 Study Group
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

This study characterizes the first clinical application of CIGB-258 in COVID-19 patients. CIGB-258 is an immunoregulatory peptide, derived from the cellular heat shock protein 60 (HSP60). Sixteen patients with COVID-19 in serious (31%) or critical (69%) conditions were included in this study. All critically ill patients recovered from the respiratory distress condition. Two of these patients had a fatal outcome due to nosocomial infections.The five seriously ill patients considerably improved. C-reactive protein (CRP) and interleukin-6 (IL-6) levels significantly decreased during treatment. CIGB-258 seems to be an effective and safe treatment option in COVID-19 patients under cytokine storm.

TRIAL REGISTRATION: RPCEC00000313

Related articles

Related articles are currently not available for this article.